arrow
M

Miguel Zugman

Hospital Israelita Albert Einstein
H指数:5
被引数:193

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

肌层浸润性膀胱癌患者根治性膀胱切除术中病理疾病升级的临床预测因素及预后意义

2025-10-090
OA
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma

抗体药物偶联物联合疗法在晚期尿路上皮癌中的疗效与安全性

2025-10-070
OAAI
VHL and TP53 mutation status are not associated with response or progression-free survival in metastatic renal cell carcinoma treated with VEGF-targeted therapies

VHL和TP53突变状态与接受VEGF靶向治疗的转移性肾细胞癌的治疗反应或无进展生存期无关。

2025-10-010
OAAI
Evaluating global disparities in clinical trial availability for renal cell carcinoma

评估肾细胞癌临床试验可及性的全球差异

2025-10-010
OAAI
Real-World efficacy and safety of belzutifan in sporadic metastatic renal cell carcinoma: a multicenter study from the city of hope enterprise

belzutifan在散发性转移性肾细胞癌中的真实世界有效性与安全性:一项来自City of Hope Enterprise的多中心研究

2025-10-010
OAAI
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma

转移性肾细胞癌患者中异常替代剪接景观的特征分析

2025-10-010
OAAI
Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials

真实世界证据表明,在乳头状肾细胞癌中,当代一线策略并未显示出生存优势:呼吁开展随机试验

2025-10-010
OA
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy

临床和病理学预测因子:在接受根治性膀胱切除术的临床淋巴结阴性的膀胱癌患者中 occult 淋巴结受累的预测因子

2025-09-010
PRE
IUC24428-85 Real-world effectiveness of ipilimumab plus nivolumab in second-line in patients with metastatic clear cell renal cell carcinoma (mccRCC) based on prior receipt of PD-1/L1 inhibitors

IUC24428-85 基于既往接受PD-1/L1抑制剂治疗的患者,伊匹木单抗联合纳武利尤单抗在二线治疗转移性透明细胞肾细胞癌(mccRCC)中的真实世界有效性

2025-08-290
OA